

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/509,941	Applicant: Stokes <i>et al</i>
Filing Date: 10/01/2004	Attorney Docket No.: 100690-1P US
Examiner: Balasubramanian, V.	Group Art Unit: 1624
Customer No.: 44992	Confirmation No.: 4973
Title: BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is being filed in response to the Office Action dated April 23, 2007, (the response date of May 23, 2007 having been extended by one month to June 23, 2007 by a Petition for Extension of Time filed concurrently herewith), in which the Examiner requires Election/Restriction of the claims in the above-identified application.

REMARKS

The Examiner has required restriction to one of the following inventions under 35 U.S.C.121 and 372:

- I. Claims 1-11, 14 and 16, drawn to a compound of formula 1 wherein ring A is unfused pyrimidine, composition and method of use.
- II. Claims 1-11, 14 and 16, drawn to a compound of formula 1 wherein ring A is a heterocyclic ring other than pyrimidine provided above, composition and method of use.

Applicants hereby elect Group II: claims 1-11, 14 and 16, drawn to a compound of formula 1 wherein ring A is a heterocyclic ring other than pyrimidine, composition and method of use. Applicants hereby choose piperidine as the ring A heterocycle all the claims (claims 1-11, 14 and 16) being readable thereon.

Application No.	10/509,941
Response Dated	06/21/2007
Reply to Office Action of	04/23/2007

The above remarks have been made without prejudice to Applicants right to prosecute any withdrawn subject matter in a timely filed continuation application.

A petition for a one-month extension of time is being filed herewith. The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100690-1P US.

Although Applicants believe no further fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100690-1P US.

Respectfully submitted,
/Carol A. Loeschorn/

Name: Carol A Loeschorn
Dated: 06/21/2007
Reg. No.: 35,590
Phone No.: 781-839-4002
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham, MA 02451